Skip to main content

Table 1 Clinical therapeutic trials for cell vaccines against PLC

From: Cellular based immunotherapy for primary liver cancer

Vaccine catalog Trial Phase Enrolled patients backgrounds Trial information
I II III Number. Location intervention comments Identifier Reference
Allogeneic    18 Sweden allogeneic dendritic cell vaccine (ilixadencel) Safety; immunological response activated against HCC NCT01974661 [20]
Autologous
I/IIa   8/12 China autologous fixed HCC vaccine Safety; recurrence delay for patients with HCC after operation [21]
     41 China autologous fixed HCC vaccine Safety; recurrence rates reduced and overall survival rates improved for patients with HCC after operation [22]
     8 USA bi-shRNAfurin/GM-CSF incorporated autologous HCC cell vaccine Safety; immunological response activated against HCC and overall survival prolonged [23]
  -    160 China autologous DC-tumor vaccine Safety; recurrence and metastasis rates for postoperative HCC patients reduced; survival rates improved [24]
     10 Japan autologous tumor lysates pulsed DC vaccine Safety; antitumor efficiency probably existed against PLC: delayed type hypersensitivity induced (7/10); tumor size shrinked (1/10); serum level of tumor marker decreased (2/10) [25]
 
   31 China autologous tumor lysates pulsed DC vaccine Safety; HCC patients’ survival better prolonged by boosters followed DCs therapy than single DCs vaccine itself [26]
     36 Japan autologous tumor lysates pulsed DC vaccine Survival for iCCA patients prolonged; prognosis improved UMIN000005820 [27]
  1. Abbreviations for the table: HCC Hepatocellular carcinoma, iCCA Intrahepatic cholangiocarcinoma, DCs Dendritic cells, GM-CSF Granulocyte macrophage colony stimulating factor, USA United States of America